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Background: The Appraisal of Guidelines for Research and Evaluation (AGREE II) tool is a validated questionnaire
used to assess the methodological quality of clinical guidelines (CGs). We used the AGREE II tool to assess the
development process, the methodological quality, and the quality of reporting of available pediatric CGs for the
management of headache in children. We also studied the variability in responses related to the characteristics of
eleven Italian neuropediatric centers, showing similarities and differences in the main recommendations reported
in CGs.
Methods: A systematic literature search was conducted from January 2002 to June 2013 on Mediline, the Cochrane
database, the National Guideline Clearinghouse website and the NHS evidence search tool, using the following
terms: headache, cephalalgia, guidelines and children (MESH or text words). Six CGs providing information on
the diagnosis and management of headache and specific recommendations for children were selected. Eleven
neuropediatric centers assessed the overall quality and the appropriateness of all available CGs using of the
AGREE II instrument.
Results: Six CGs meeting the inclusion and exclusion criteria were identified and assessed by 11 reviewers. Our
study showed that the NICE CGs was “strongly recommended” while the French and Danish CGs were mainly
“not recommended”. The comparison between the overall quality score of the French CGs and the NICE CGs was
statistically significant (6.54 ± 0.69 vs 4.18 ± 1.08; p =0.001). The correlation analysis between quality domain score
and guideline publication date showed a statistically significant association only for the “editorial independence”
domain (r = 0.842 p = 0.035). The intra-class coefficients showed that the 11 reviewers had the highest agreement
for the Lewis CGs (r = 0.857), and the lowest one for the NICE CGs (r = 0.656). Statistical analyses showed that
professionals from outpatient services dedicated pediatric headache assigned a higher overall quality score to the
NICE CGs as compared to professionals from non-outpatient services (6.86 ± 0.38 vs 6.0 ± 0.82; p = 0.038).
Conclusions: CGs resulted definitely of low-moderate quality and non “homogeneous”. Further major efforts are
needed to update the existing CGs according to the principles of evidence based medicine.
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About ten years ago, the World Health Organization
(WHO) acknowledging the relevance of the issue,
launched a global campaign to reduce the burden of
headache, in collaboration with three major international
headache non-governmental organization [1].
Headache is very frequently reported among children,
even more frequently than among adults. It can have a
strong impact on school performance [2], being the
major cause of absence from school [3], and widely af-
fecting other daily activities [4].
The individual and societal costs of headache disorders
in children and adolescents are due to the high incidence,
prevalence and lifetime prevalence of these conditions. In
particular, the lifetime prevalence of headache disorders
ranges from 70% to 80% in children of 13–15 years of age
[5,6], while the lifetime prevalence of headache, consider-
ing all decades and according to both age- and gender-
dependent variables, ranges between 12% and 18% as
reported in international community-based studies [7].
A recent review of 64 cross-sectional studies reports
an overall mean prevalence of headache of 54.4% and an
overall mean prevalence of migraine of 9.1%. The mean
prevalence of headache reported for girls was 59.2%,
while for boys was 49.3%, while the mean prevalence of
migraine was 10.5% for girls and 7.6% for boys [8].
Headache affects 3% to 8% of children aged ≥3 years,
19.5% of children aged 5, and 37% to 51.5% of children
aged 7 [9,10], with an higher frequency in males before
puberty, and in females after puberty [11].
A study based on parental reports may be an unreli-
able source of information on the frequency of headache
in young children. In fact, it has been suggested that
almost 36% of parents are unaware of their children
suffering from headache [12]. Moreover, the increased
incidence observed over the last 30 years is probably due
to significant changes in children’s lifestyle [13].
Given the its high prevalence and the high degree of
disability it can cause, it is no surprise that headache has
become a relevant public health issue. Managing this
condition, in fact, has its direct and indirect costs for the
National Health Care System (NHCS), which are consid-
erable and not easy to quantify, as children are not directly
involved in the production cycle [14].
Agreement among independent physicians in the diag-
nosis of headache in children is often surprisingly poor
and not adequately investigated [15]. Both the second
[16] and the recently published third version [17] of the
International Classification Headache Disorders (ICHD-
III), stressed the need of more specific diagnostic criteria
to increase the sensitivity, specificity and positive pre-
dictive value of the diagnosis of headache in children,
which should be based not only on signs and symptoms,
but also on the “behavior” and on some additional andpeculiar diagnostic features (such as, moving into a dark
room, squinting, turning off lights or photophobia,
pallor, abdominal pain and many other autonomic signs
and symptoms, increased sensitivity to odors or osmo-
phobia) [18].
A further issue to be faced is the diagnosis and treat-
ment of headaches in Pediatric Emergency Department.
Children diagnosed and treated by healthcare profes-
sionals who are not expert in pediatric neurology, might
risk to undergo inappropriate, unnecessary and harmful
neuroradiological investigations.
Therefore, physicians facing this complex and multifa-
ceted issues need appropriate CGs for the assessment,
diagnosis and treatment of headaches in children.
The Appraisal of Guidelines for Research and Evaluation
(AGREE II) assessment tool is a validated questionnaire
used to assess the methodological quality of clinical
guidelines (CGs) [19]. It has also been adopted by the
World Health Organization (WHO) for the assessment
of CGs [20].
This study aimed at using the AGREE II tool to assess
the guideline development process, the quality of report-
ing of available pediatric CGs for the management of
headache. The secondary endpoint was to assess the vari-
ability of provided answers in relation to the characteris-
tics of each Italian SINP (Società Italiana di Neurologia
Pediatrica) center enrolled in the study. A last objective
was to identify similarities and differences in the main rec-
ommendations reported in the included CGs.
Methods
Available CGs published from January 2002 to June
2013 were searched in Medline, the Cochrane, database,
the National Guideline Clearinghouse website, and
through the NHS evidence search service from using the
following terms: “headache” or “cephalalgia”, and “practice
guideline type” and “children” (MESH or text words). Fur-
ther searches were carried out on the web sites of the
main agencies that produce CGs, such as NICE (www.
nice.org.uk), SIGN (www.sign.ac.uk), and SNLG (www.
snlg-iss.it), and on the websites of scientific societies spe-
cialized in headache, such as the Italian Society for the
Study of Headaches (www.sisc.it).
We included all CGs on the diagnosis and management
of headache that included specific recommendations on
infants and children. Guidelines referring exclusively to
adults were excluded, and so were studies referring to
previous publication.
The AGREE II tool is an international validated instru-
ment for the assessment of the methodological quality of
the CGs development process. The tool consists of 23
items organized in 6 domains: scope and purpose (3 items),
stakeholder involvement (3 items), rigor of development
(8 items), clarity and presentation (3 items), applicability
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is scored with a 7-point Likert scale.
Scores range from 7 (strongly agree) to 1 (strongly dis-
agree). The domain score is expressed as a percentage of
the maximum possible score for that domain and is ob-
tained by summing the scores of individual items.
One last item provides an overall judgment on the
quality of the CGs, with a score ranging from 7 (higher
possible quality) to 1 (lower possible quality).
A further 3-point scale (1 = not recommended- NR;
2 = recommended with provisos or modifications- R, and
3 = strongly recommended- SR) is included in the tool,
which provides an overall judgment on whether the CGs
should be recommended for use. Even though a threshold
score is not defined, a domain score < 50% is usually con-
sidered of limited use.
All the 11 Italian centers specialized in the diagnosis
and management of headache in children that refer to
the SINP (Società Italiana di Neurologia Pediatrica),
were included in the study. Eleven referents from all the
included centers assessed the 6 CGs using the AGREE II
instrument. Moreover, a specific questionnaire was ad-
ministered to all referents to collect the following infor-
mation: age, sex, years of specialization, years of clinical
practice in the field of pediatric headache, presence in
the center of an outpatient service for children with
headache, number of first visits in 2012, number of con-
trol visits in 2012, number of patients visited in 2012,
presence in the center of an emergency unit, estimate of
the number of patients administered pharmacological
treatments and non-pharmacological treatments, and esti-
mate of the number of patients administered both treat-
ments. The answers provided by the 11 references to this
questionnaire were associated with those provided by the
same referents to the AGREE II tool.
Statistical analyses were performed using t-tests for
continuous variables and chi square tests for categorical
variables. A correlation analysis between the answers
provided to the AGREE II tool and specific variables
collected through the additional questionnaire was also
performed using the Pearson’s index. The intraclass co-
efficient correlation was used as measure of agreement
between the 11 reviewers.
Data were analyzed with SPSS (version 21.0). A p
value ≤ of 0.05 was considered as significant.
Results
A total of six CGs were identified through Medline and
the web sites of the main international guideline agencies
and scientific societies [21-26].
Table 1 shows the AGREE II domain scores of the 6
GCs as assessed by the 11 reviewers. The NICE CGs [26]
was judged as “strongly recommended” by 8 reviewers
and “recommended with modifications” by 3 reviewers,while the French CGs [24] was “not recommended”
by 5 reviewers, “recommended with modifications” by
5 reviewer and “strongly recommended” by 1 reviewer
(Table 1). The difference between the overall quality
scores of the NICE CGs and the French CGs was statisti-
cally significant (6.54 ± 0.69 vs 4.18 ± 1.08; p =0.001).
The “scope and purpose” domain is designed to assess
the overall aim, the clinical questions covered by the
CGs, and the patients to whom the CGs is meant to
apply. The median score for this domain was 73.5%
(range 60.6%-92.9%) with none of the included CG scor-
ing < 50%.
The “stakeholder involvement” domain is meant to as-
sess the degree of involvement in the development
process of subjects from all the relevant professional
groups, whether patients’ views and preferences have
been sought, and the definition of the target users of the
CGs. The median score for this domain was 55.5%
(range 49%-86.4%) with only one CG scoring < 50% [23].
The “rigor of development” domain is aimed at asses-
sing the methods used to search and select evidence,
and to define the recommendations, and whether the
health benefits, side effects, and risks have been consid-
ered. This domain also assesses the explicit link between
the recommendations and the supporting evidence,
whether the CGs has been externally reviewed by ex-
perts prior to its publication, and if a specific procedure
for updating the CGs is provided. The median score for
this domain was 63.1% (range 37.5% - 90.7%), with two
CG scoring < 50% [24,25].
The “clarity and presentation” domain addresses the de-
gree of clarity of the recommendations and the different
options for the management of the target condition, and if
the key recommendations are easily identifiable. The
median score for this domain was 72.2% (range 64.1% -
94.9%) with none of the included CG scoring < 50%.
The “applicability” domain aims at assessing if the
guideline is supported with tools for its application, and
if the possible presence of organizational barriers to the
implementation of the recommendations is discussed.
This domain also assesses if the potential costs derived
by the implementation of the recommendations are
taken into account and if the CGs provide indications for
the monitoring and/or audit process. The median score
for this domain was 44.1% (range 31.4% - 75.4%) with five
CG scoring < 50% [21-26].
The “editorial independence” domain is designed to
assess the degree of independence from funding sources
and the reporting of conflicts of interest by the CG
development group. The median score for this domain
was 59.1% (range 41.7% - 74.2%) with only one CG scor-
ing < 50% [22].
A correlation analysis between the quality domain
scores and the CGs’ publication date showed a statistically
Table 1 AGREE II domain scores of the included CGs on the management of headache in children
Guideline
reference
Year Diagnosis
and/or
treatment
Population Domain 1 Domain 2 Domain 3 Domain 4 Domain 5 Domain 6 Overall quality
score (range 1-7)
(M ± SD)
Overall assessment
usage recommendations
(n = 11)*
Scope and
purpose %
Stakeholder
involvement %
Rigor of
development %
Clarity and
presentation %
Applicability % Editorial
indipendence %
Lewis [21] 2002 Diagnosis Children and
adolescents
82.3 53 72.9 82.8 48.9 53 5.45 ± 1.13 SR = 8 (72.7%); R = 2 (18.2%)
NR = 1 (9.1%)
SISC [22] 2003 Diagnosis
and treatment
Children and
adolescents
67.2 81.3 57.8 64.1 43.6 41.7 4.73 ± 1.49 SR = 3 (27.3%); R =5 (45.4%)
NR = 3 (27.3%)
Lewis [23] 2004 Treatment Children and
adolescents
79.8 49 68.4 77.3 44.7 61.4 5.36 ± 0.81 SR = 5 (45.4%); R = 6 (54.6%)
Geraud
[24]
2004 Diagnosis
and treatment
Adult and
children
60.6 55 42.8 67.2 31.4 56.8 4.18 ± 1.08 SR = 1 (9.1%); R = 5 (45.4%)
NR = 5 (45.4%)
Bendtsen
[25]
2012 Diagnosis
and treatment
Adult and
children
62.6 56.1 37.5 65.7 36 68.9 4.18 ± 1.54 SR =5 (45.4%); R =1 (9.1%)
NR = 5 (45.4%)
NICE [26] 2012 Diagnosis
and treatment
Adult and
young people
92.9 86.4 90.7 94.9 75.4 74.2 6.54 ± 0.69 SR = 8 (72.7%); R = 3 (27.3%)
AGREE = Appraisal of Guidelines for Research and Evaluation; CGs = Clinical Guidelines.
SR = Strongly recommended; R = Recommended with modification; NR = Not recommended.
*number of pediatrics included in the study.
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ence” domain (r = 0.842 p = 0.035) (Figure 1).
The intraclass coefficients showed that the 11 reviewers
reached the higher agreement when assessing the Lewis
[21] CGs (r = 0.857), and the lower agreement when
assessing the NICE CGs (r = 0.656) (Table 2). This is
why the NICE CGs obtained the higher overall quality
score, but with the lower agreement among reviewers
(Tables 1 and 2).
Correlations between results from the assessment with
the AGREE-II tool and the characteristics reported by
the 11 reviewers were also investigated. The characteris-
tics of the reviewers were collected through a specific
questionnaire. Results from the questionnaire showed a
wide heterogeneity in all the considered variables (Table 3).
Statistical analyses showed that professionals from out-
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Figure 1 Quality domain scores according to guideline publication da
[25]; 6. NICE [26]. For each numeric value of the caption matches a guidelinhigher overall quality scores to the NICE CGs compared
to those who do not work in similar structures (6.86 ±
0.38 vs 6.0 ± 0.82; p = 0.038). Reviewers who did not rec-
ommend the French CGs (n = 5) visited more patients in
2012 (a median value higher than 340) compared to those
who recommended the CGs (R +NR= 6)(p = 0.036).
Borderline significant correlations were observed be-
tween years of specialization in pediatrics of the referents
and the overall scores assigned in the items of “editorial
independence” domain (r = 0.535; p = 0.09), and between
the overall quality scores assigned to all CGs and the
number of control visits carried out by each participating
center in 2012 (r = 0.503; p = 0.11). An inverse correlation
was observed between years of clinical practice in
pediatric headache of the referents and the overall scores
assigned to the items in the “rigor of development” do-
main (r = − 0.526; p = 0.10).0
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Table 2 Assessment of the agreement among the 11
referents that assessed CGs with the AGREE II instrument
Guideline reference Year Intraclass correlation
coefficient
CI 95%
Lewis [21] 2002 0.857 0.752 - 0.930
SISC [22] 2003 0.736 0.542 - 0.871
Lewis [23] 2004 0.804 0.660 - 0.904
Geraud [24] 2004 0.740 0.558 - 0.875
Bendtsen [25] 2012 0.745 0.548 - 0.873
NICE [26] 2012 0.656 0.404 - 0.832
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overall quality scores assigned to each CGs and the
age (r = − 0.352), years of specialization (r = − 0.190),
years of clinical practice in the field of children headache
(r = − 0.376) and number of patients visited in 2012
(r = 0.487), but none of them was statistically significant.
Discussion
In this study, we used the AGREE II questionnaire [19],
a validated tool that had never been used before to assess
the methodological quality of pediatric CGs, to assess the
clinical practice CG development process, and the meth-
odological quality and the quality of reporting of all avail-
able pediatric CGs for the management of headache.
Comparing available recommendations, the first data
that clearly emerged (Table 1), was that the French and
Danish CGs [24,25] scored both lower than the other
available CGs, for the domain 3 (“Rigor of Development”:
respectively, 42.8% and 37.5%) and domain 5 (“Applicabil-
ity”: respectively, 31.4% and 36%). Five (45.4%) of the 11
referents from the SINP centers, according to these data,
rated both CGs as “not recommended” (NR). These re-
sults are much likely due to the French and Danish CGs
being focused on adults, with a minor section dedicated toTable 3 Clinical profile of the 11 referents that assessed the i
characteristics of their clinical centers
Variables
Age (yrs)
Sex (M/F)
Years of specialization (yrs)
Years of clinical practice in headache children (yrs)
Is there a dedicated ambulatory service to children headache? (Y/N)
First ambulatory visits in 2012 year
Control ambulatory visits in 2012 year
Total ambulatory visits in 2012 year
Is there an emergency department? (Y/N)
Estimate of patients on pharmacological treatment (%)
Estimate of patients on non-pharmacological treatment (%)
Estimate of patients on both treatments (%)the “diagnosis and treatment of headaches in developmen-
tal age”. This implies that both the French and Danish
CGs, despite the lapse of eight years between their publi-
cation, are similarly unclear, with scarce information on
children and adolescents, and are therefore poorly if not
applicable. In fact, even though a threshold score is not
defined, a domain score < 50% is usually considered as
stated in the “methods” section, of limited use. Interest-
ingly, the French CGs were “strongly recommended” (SR)
by only 1 of the 11 referents (9.1%) and “recommended
with modification” (R) by 5/11 referents (45.5%), while
the Danish CGs received an exactly symmetrical score
(respectively SR in 5/11 referents versus R in only 1 of
them) (Table 1). These apparently conflicting data are
balanced by those emerging from the “assessment of the
agreement among the referents” reported in Table 2.
This last statistical analysis of data is much more reli-
able than the overall assessment (Table 1), as it takes
into account the “score” (Table 2) and not only an over-
all judgment on whether or not the CGs ought to be
recommended (Table 1). In particular, Table 2 reports
an interclass correlation coefficient of 0.740 for the
French CG and of 0.745 for the Danish CGs, that is, two
coefficients that can be considered practically overlap-
ping (Table 2). The SR and R categories assigned in
Table 2 to each CGs by the referents (see the legend for
overall assessment usage recommendations) are much
likely strongly affected by other important variables re-
lated to the characteristics of the center, as shown in
Table 3.
Comparing the overall quality (Table 1), the NICE
CGs (26) showed significantly higher scores versus the
French and Danish CGs, thus CGs, being by far the best
available CGs (6.54 ± 0.69 vs 4.18 ± 1.08; p =0.001)
(Table 1). The NICE CGs showed also, the best scores
for each domain and area (NICE CGs were “stronglyncluded CGs with the AGREE II instrument and
M± SD Median Range
43.8 ± 11 39 32-64
7/4 - -
13.6 ± 11 9 0-33
13.6 ± 9.3 10 3-30
7/4 - -
238 ± 262 110 20-900
382 ± 421 250 40-1500
620 ± 681 340 60- 2400
9/2 - -
58 60 40-80
28 25 5-50
26 20 10-75
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with modifications” by 3/11 reviewers, and “not recom-
mended” by 0/11 reviewers).
However, some of the inconsistencies observed in the
statistical analysis of results (as for the comparison
between French and Danish CGs shown above) appeared
to be even more evident for some aspects of the NICE
CGs. A deeper analysis of NICE CGs, in fact, showed a
lower intra-class correlation coefficient score (assessment
of agreement between referents from 11 SINP Centers)
(r = 0.656) (Table 2). This apparently strong inconsist-
ency in the assessment of the NICE CGs among different
SINP Centers can be explained by a different experience
of the referents in the diagnosis and treatment of head-
aches in children. In particular, our analyses showed that
some variables related to single SINP Centers (see the
wide range of values reported in Table 3 for the variables
“First, Control and Total, Ambulatory visits in 2012”, and
“Years of the clinical practice”), can significantly vary
according to the referents’ clinical profile, and to the char-
acteristics of their clinical centers (Table 3). In other
words, even though the 11 SINP centers included in this
study are the most relevant and expert in the diagnosis
and management of headache in children, referents from
units such as pediatric neurology outpatient services with
a higher number of first visits were able to give more
appropriate and inconsistent answers in the assessment
with AGREE II. Specifically, the answers provided by 11
reviewers (Table 3) showed a wide heterogeneity for
all considered variables. Overall, professionals from
outpatient services specialized in pediatric headache
assigned higher overall quality scores to the NICE CGs
compared to those who do not work in similar structures
(6.86 ± 0.38 vs 6.0 ± 0.82; p = 0.038).
Furthermore, reviewers who did not recommend the
French CGs (n = 5) visited more patients in 2012 (a median
value higher than 340) compared to those that recommen-
ded the same guideline (R +NR = 6) (p = 0.036).
The “scope and purpose” domain is designed to assess
the overall aim and the clinical questions covered by the
considered CGs (Table 1), and the patients to whom the
CG is meant to apply. None of the CGs included in this
study scored < 50% (range 60.6%-92.9%). Only one of the
included CGs (23) scored < 50% (range 49%-86.4%) in
the “stakeholder involvement” domain (degree of involve-
ment of individuals from all the relevant professional
groups and patients’ views and preferences), while none of
the included CGs scored < 50% in the “clarity and pre-
sentation” domain. Data from the “applicability domain”
are remarkable, as only the NICE CGs [26] scored 75.4%,
while all the other CGs (21–25) showed values < 50%.
Correlation analyses between year of specialization in
pediatrics and overall scores in the items of the “editorial
independence” domain (r = 0.535; p = 0.09), and betweenthe overall quality scores in the assessment of CGs
and the number of control visits during 2012 (r = 0.503;
p = 0.11) showed borderline significant results. An inverse
correlation was observed between years of clinical practice
in the field of pediatric headache and the overall scores
assigned to the items of the “rigor of development” do-
main (r = − 0.526; p = 0.10).
One of the few positive aspects of the assessment is
the “editorial independence” (the degree of independ-
ence from funding sources and the reporting of conflicts
of interest by the CG development group ), which shows
a progressive and significant increase from 2002 to 2012
(Figure 1), with a median score for the domain of 59.1%
(range 41.7% - 74.2%) and only one CGs scoring < 50%
[22]. Conflict of interest and editorial independence can
be a relevant source of bias in the development of CGs,
and high rates of conflict of interest among CGs authors
have been reported in the past. The rates of disclosure
conflict of interest by authors, and the availability to the
public of this type of information are still unacceptably
low, even though the rates of conflict of interest among
guideline authors are currently decreasing [27]. A correl-
ation analysis between quality domain score and guide-
line publication date, in particular, showed a statistically
significant association for the “editorial independence”
domain only (r = 0.842 p = 0.035) (Figure 1). This means
that only one domain improves, from a qualitative point
of view, in eleven years of CG production (Figure 1).
How can this aspect be explained? Understanding why
all other domains and areas of the AGREE II instrument
did not significantly improved from 2002 to 2012, would
probably be, in our opinion, much more useful than
understanding the reason of the increase in the “editorial
independence”, domain (Figure 1).
The “evidence based medicine” approach in the field
of pediatric headache is unquestionably poor. Pediatri-
cians admit that they would be more inclined to follow
CGs if these were evidence-based, and therefore proved
to improve outcomes [28]. Similarly, a study on Australian
general practitioners showed that the most important
factor leading the decision whether to follow a guideline
or not, was its being evidence-based [29]. We believe that
the reason for the lack of evidence on pediatric headache
is to be found in the scarcity of funds devolved to research
in pharmacological and non-pharmacological treatments
for headaches in children . One of the reasons preventing
either private or public investors from funding clinical
studies in this field is the small expected difference
between experimental drugs and placebo in children
with headache, which means a huge sample is to be
enrolled to see such a small effect. These issues are
the reason why a number children, actually a small num-
ber due to the risk this practice implies, are prescribed
drugs off label.
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and hyper-specialized education that characterizes this
medical field. Specialists in “headache” can, in fact, come
from specializations such as neurology, pediatrics, internal
medicine, child neuropsychiatry. Addressing this issue is
crucial to uniform the diagnosis, treatment and manage-
ment of children with headache. The existence of this
issue can also at least partially explain the conflicting
results from the assessment carried out with the AGREE
II tool. All CGs analyzed with the AGREE II tool in this
paper refer to the criteria published in the International
Classification of Headache Disorders (ICHD) for diagnos-
tic purposes. Unfortunately, the first edition of he ICHD
(ICHD-I) [30], which has been in use from 1988 to 2004,
did not provide a clear distinction between diagnostic cri-
teria for children and those for adults. This distinction
was implemented in 2004 (ICHD II) [16] and maintained
onwards this differentiation. The last edition of the ICHD,
the “third” edition (ICHD III), has been published in July
2013 [17] because the issue of diagnosis is therefore rele-
vant, as among the CGs included in the present paper
(Table 1), only those published in 2012 [26] refer to diag-
nostic criteria specifically designed for children, while all
other CGs (Table 1) published before the ICHD-II [16]
refer to generic criteria.
Data on acute therapies for children with headaches
are also few, but more consistent (acetaminophene, ibu-
profene and triptans, for children older than 12 years),
considering patients’ preferences, comorbidities and the
risk of adverse events. Topiramate has recently [25,26]
proved effective, safe and well tolerated for prophylactic
purposes, while flunarizine, valproate and beta-blockers
are already included in previously published CGs [22-24].
However, no drugs for the prevention of migraine in
children are currently approved by both the Food & Drug
Administration and European Medicine Agency, there-
fore, pediatricians are forced to prescribe drugs approved
for adults or off-label (approved for clinical conditions
other than migraine prevention).
To summarize an overall judgment of the existing CGs
on the diagnosis and treatment of headaches in children,
we can say, without any doubt, that currently available
CGs are of low-moderate quality and non “homoge-
neous”. Huge gaps between literature-based evidence
and best practice are not infrequent. This makes evident
that the act of developing CGs is not enough, by itself,
to change the everyday practice [31,32]. The existence of
CGs does not change the practice if the reasons for
changing are not evident to all professionals involved in
the management of patients with a given condition. The
success or failure of CGs is multi-factorial and is related
to the characteristics of the development process and
the implementation, to the provider and the patient be-
liefs and preferences, to the therapeutic setting, and tothe limitations of methodological quality. However, one
of the primary objective of CGs is its being be oriented
toward the target population and/or setting in which it
is meant to be applied (e.g. children), and only CGs
oriented towards subjects of all age ranges could
guarantee the highest compliance and could actually
change clinical practice and eventually increase pa-
tients’ quality of life.
Additional RCTs and more controlled data are needed
to help clinicians choose the most appropriate drugs for
the treatment of this common clinical problem. New
and innovative study designs are required to this pur-
pose, to minimize the high placebo response observed in
pediatric populations.
Conclusion
In conclusion, this survey, which was carried out on
behalf of the “Pediatric Headache Commission” of SINP,
highlights that further research is strongly needed in this
area, and that existing CGs should be updated basing on
the principles of evidence based medicine.
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